Defence Therapeutics (TSE:DTC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Defence Therapeutics Inc. has announced that its AccuTOX® technology not only kills tumors but also boosts the immune system, significantly enhancing the effectiveness of Immune Checkpoint Inhibitors (ICI) in treating solid tumors. AccuTOX® achieves this by converting ‘cold’ tumors, which typically resist ICI treatment, into ‘hot’ tumors that are more vulnerable to immune attack. The company has observed a tenfold increase in treatment efficacy in preclinical studies and sees AccuTOX® as a potential game-changer for increasing the patient population eligible for ICI treatment.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.